Guslandi M
Istituto di Medicina Interna, Università degli Studi di Milano.
Minerva Med. 1990 Dec;81(12):855-60.
Levo-sulpiride is a substituted benzamide with antiemetic activity 3-8 times more potent than the racemic form and the d-isomer. Its mode of action is partially central (inhibition of dopaminergic receptors at the trigger zone for vomiting) and partially peripheral (normalization of motor activity of stomach and gall-bladder). The drug was found effective in the prevention of chemotherapy-induced and post-operative vomiting as well as in the treatment of nausea and vomiting during hepatic, biliary and gastroduodenal disorders, organic and functional dyspepsia, motion sickness and vertigo. Levo-sulpiride is at least as effective as domperidone, antihistamines and neuroleptic agents. Compared with the latter drugs and with d-sulpiride and the racemus, l-sulpiride is much better tolerated. Drowsiness is reported only at high doses, and no clinical signs of hyperprolactinaemia are observed, even after prolonged treatment.
左舒必利是一种取代苯甲酰胺，其止吐活性比消旋体和d -异构体强3 - 8倍。其作用方式部分是中枢性的（抑制呕吐触发区的多巴胺能受体），部分是外周性的（使胃和胆囊的运动活动正常化）。该药物在预防化疗引起的呕吐和术后呕吐以及治疗肝、胆和胃十二指肠疾病、器质性和功能性消化不良、晕动病和眩晕期间的恶心和呕吐方面被发现有效。左舒必利至少与多潘立酮、抗组胺药和抗精神病药物一样有效。与后几种药物以及d -舒必利和消旋体相比，左舒必利的耐受性要好得多。仅在高剂量时才报告有嗜睡现象，即使经过长期治疗也未观察到高催乳素血症的临床症状。
